3rd Quarter Results-Part 2

AstraZeneca PLC
24 October 2002


Part 2

Consolidated Profit & Loss Account For Continuing Operations


                                                                                           2002              2001
For the nine months ended 30 September                                                                 (Restated)
                                                                                             $m                $m

Sales                                                                                   13,153            12,040

Cost of sales                                                                           (3,480)           (3,250)
Distribution costs                                                                        (102)              (89)
Research and development                                                                (2,177)           (1,955)
Selling, general and administrative expenses                                            (4,337)           (3,984)
Other operating income                                                                     225               304
Operating profit before exceptional items                                                3,282             3,066

Exceptional items charged to operating profit                                                -              (126)
Operating profit                                                                         3,282             2,940
Share of joint ventures' and associates' operating profits                                   -                 -
Profit on sale of fixed assets                                                               -                10
Net interest and dividend income                                                            24               101
Profit on ordinary activities before taxation                                            3,306             3,051

Taxation                                                                                  (886)             (864)
Profit on ordinary activities after taxation                                             2,420             2,187

Attributable to minorities                                                                 (12)               (7)
Net profit for the period                                                                2,408             2,180

Dividends to Shareholders                                                                 (398)             (405)
Profit retained for the period                                                           2,010             1,775


Earnings per Ordinary Share before exceptional items                                     $1.39             $1.28
Earnings per Ordinary Share                                                              $1.39             $1.23
Diluted earnings per Ordinary Share                                                      $1.39             $1.23
Weighted average number of Ordinary Shares in issue (millions)                           1,736             1,762
Diluted average number of Ordinary Shares in issue (millions)                            1,739             1,764




Consolidated Profit & Loss Account For Continuing Operations


                                                                                           2002              2001

For the quarter ended 30 September                                                                     (Restated)

                                                                                             $m                $m
Sales                                                                                    4,350             3,950

Cost of sales                                                                           (1,181)           (1,064)
Distribution costs                                                                         (37)              (29)
Research and development                                                                  (757)             (614)
Selling, general and administrative expenses                                            (1,468)           (1,324)
Other operating income                                                                      14                96
Operating profit before exceptional items                                                  921             1,015

Exceptional items charged to operating profit                                                -               (45)
Operating profit                                                                           921               970
Share of joint ventures' and associates' operating profits                                   -                 -
Profit on sale of fixed assets                                                               -                 -
Net interest and dividend income                                                             2                23
Profit on ordinary activities before taxation                                              923               993

Taxation                                                                                  (242)             (280)
Profit on ordinary activities after taxation                                               681               713

Attributable to minorities                                                                  (6)               (2)
Net profit for the period                                                                  675               711

Dividends to Shareholders                                                                    -                 -
Profit retained for the period                                                             675               711


Earnings per Ordinary Share before exceptional items                                     $0.39             $0.42
Earnings per Ordinary Share                                                              $0.39             $0.40
Diluted earnings per Ordinary Share                                                      $0.39             $0.40
Weighted average number of Ordinary Shares in issue (millions)                           1,728             1,757
Diluted average number of Ordinary Shares in issue (millions)                            1,730             1,759






Consolidated Balance Sheet


                                                                                           2002              2001

As at 30 September                                                                                     (Restated)

                                                                                             $m                $m
Fixed assets                                                                             9,023             7,929

Current assets                                                                          11,557            11,137
Total Assets                                                                            20,580            19,066

Creditors due within one year                                                           (6,916)           (6,391)

Net current assets                                                                       4,641             4,746

Total assets less current liabilities                                                   13,664            12,675

Creditors due after more than one year                                                    (491)             (909)
Provisions for liabilities and charges                                                  (1,596)           (1,795)
Net assets                                                                              11,577             9,971
Capital and reserves
Shareholders' funds and minority interests                                              11,577             9,971






Consolidated Cash Flow Statement


                                                                                           2002              2001
For the nine months ended 30 September                                                       $m                $m
Cash flow from operating activities

Operating profit before exceptional items                                                3,282             3,066
Depreciation and amortisation                                                              700               633

Decrease/(increase) in working capital and other non-cash
movements                                                                                  153              (436)

Net cash inflow from operating activities before exceptional
  items                                                                                  4,135             3,263

Outflow related to exceptional items                                                       (74)             (280)

Net cash inflow from operating activities                                                4,061             2,983

Returns on investments and servicing of finance                                             42               137
Tax paid                                                                                  (678)             (631)
Capital expenditure and financial investment                                            (1,034)             (990)
Acquisitions and disposals                                                                   -               (44)
Equity dividends paid to Shareholders                                                     (820)             (830)
Net cash inflow before management of liquid resources and
  financing                                                                              1,571               625
Net (purchase)/issues of shares                                                           (871)             (702)
Exchange and other movements                                                                56               (51)
Increase/(decrease) in net cash funds in the period                                        756              (128)

Net cash funds at beginning of period                                                    2,867             3,605
Net cash funds at end of period                                                          3,623             3,477








Notes to the Interim Financial Statements



1                BASIS OF PREPARATION AND ACCOUNTING POLICIES

The unaudited financial statements for the nine months ended 30 September 2002
have been prepared in accordance with UK generally accepted accounting
principles.  The accounting policies applied are those set out in AstraZeneca
PLC's 2001 Annual Report and Form 20-F except that, in the current period,
AstraZeneca adopted Financial Reporting Standard No. 19 'Deferred Tax'.  Prior
periods have been restated and the effects of this restatement were to reduce
profits for the nine months ended 30 September 2001 by $28m and reduce net
assets at that date by $164m.  On adoption net assets at 1 January 2002 were
reduced by $193m.  The table below illustrates the effect on EPS before
exceptional items of this restatement.

The statements do not constitute statutory accounts of the group within the
meaning of Section 240 of the Companies Act 1985.  Statutory accounts for the
year ended 31 December 2001 have been filed with the Registrar of Companies.
The auditor's report on those accounts was unqualified and did not contain any
statement under Section 237 of the Companies Act 1985.



2001 TAXATION AND EARNINGS PER SHARE BEFORE EXCEPTIONAL ITEMS

                                                 Q1 2001      Q2 2001      Q3 2001      Q4 2001           Year

Tax charge before adoption of FRS 19 ($m)          (316)        (269)        (286)        (282)        (1,153)
Tax charge after adoption of FRS 19 ($m)           (315)        (289)        (295)        (315)        (1,214)
Published EPS before adoption of FRS 19 ($)        0.45    .    0.42         0.43         0.47           1.77

Adjusted EPS after adoption of FRS 19 ($)          0.45         0.41         0.42         0.45           1.73



2          JOINT VENTURES AND ASSOCIATES

The group's share of joint ventures' sales for the nine months to 30 September
2002 amounted to $184m and $171m for the comparative period.  Share of joint
ventures' operating profits for the nine months to 30 September 2002, and for
the comparative period, were $nil.



3          NET CASH FUNDS

The table below provides an analysis of net cash funds and a reconciliation of
net cash flow to movement in net cash funds.


                                          At 1 Jan             Cash           Other        Exchange      At 30 Sept

                                              2002             flow        non-cash       movements            2002

                                                $m               $m              $m              $m              $m
Loans due after 1 year                       (635)              14             284               -            (337)

Current instalments of loans                 (107)              41            (284)             (3)           (353)

Total loans                                  (742)              55               -              (3)           (690)
Short-term investments                      3,118              596               -              32           3,746
Cash                                          705             (11)*              -              22             716
Overdrafts                                   (195)              48*              -              (1)           (148)
Short-term borrowings, excluding
overdrafts                                    (19)              12               -               6              (1)
                                            3,609              645               -              59           4,313
Net cash funds                              2,867              700               -              56           3,623

Issue of AstraZeneca PLC Ordinary
Shares                                                         (25)
Repurchase of AstraZeneca PLC
Ordinary Shares                                                896
Net cash inflow before
management of liquid resources and
financing                                                     1,571



* Movement of $37m on cash and overdrafts corresponds to increase in cash during
period as defined under UK GAAP.



4         LEGAL PROCEEDINGS

Further to note 36 to the Financial Statements found on page 94 in the
AstraZeneca 2001 Annual Report and Form 20-F wherein reference is made to
various investigations into drug marketing and pricing practices in the US, the
US Department of Justice has been conducting an investigation into the sales and
marketing of Zoladex (goserelin acetate implant).  The Company has been informed
that the investigation was prompted by the filing of a qui tam complaint by a
private party and involves allegations of improper submission of claims to the
Medicare program. The Company is cooperating with the investigation, which is
ongoing.  While it is not possible to predict the outcome of the investigation,
management is of the opinion that the ultimate disposition should not have a
material adverse effect on AstraZeneca's financial position or results.

5         NINE MONTHS TERRITORIAL SALES ANALYSIS

                                                                                          % Growth
                                                Nine Months      Nine Months

                                                       2002             2001                        Constant

                                                         $m               $m          Actual        Currency
       USA                                            6,963            6,425              8               8

       Canada                                           423              383             10              12
       North America                                  7,386            6,808              8               8
       France                                           826              701             18              15
       UK                                               486              551            (12)            (13)
       Germany                                          512              511              -              (3)
       Italy                                            551              457             21              18
       Sweden                                           210              199              6               5
       Europe others                                  1,610            1,400             15              12
       Total Europe                                   4,195            3,819             10               7
       Japan                                            663              591             12              19
       Rest of World                                    909              822             11              14
Total                                                13,153           12,040              9               9



6         THIRD QUARTER TERRITORIAL SALES ANALYSIS

                                                                                          % Growth
                                                        3rd              3rd
                                                    Quarter
                                                                     Quarter
                                                       2002
                                                                        2001                        Constant
                                                         $m
                                                                          $m          Actual        Currency
       USA                                            2,244            2,166              4               4

       Canada                                           150              129             16              16
       North America                                  2,394            2,295              4               4
       France                                           289              219             32              17
       UK                                               156              181            (14)            (20)
       Germany                                          177              163              9              (3)
       Italy                                            172              120             43              26
       Sweden                                            72               57             26              10
       Europe others                                    524              430             22               9
       Total Europe                                   1,390            1,170             19               6
       Japan                                            251              202             24              23
       Rest of World                                    315              283             11              13
Total                                                 4,350            3,950             10               6









7              NINE MONTHS PRODUCT SALES ANALYSIS


                                                         World                                      US
                                         Nine         Nine                  Constant           Nine
                                       Months       Months       Actual     Currency         Months         Actual
                                         2002         2001       Growth       Growth           2002         Growth
                                           $m           $m            %            %             $m              %
Gastrointestinal:

Losec                                   3,578        4,287         (17)         (17)          2,221           (22)
Nexium                                  1,323          295         n/m          n/m           1,031           n/m
Others                                     45           30          50           50              13             -
Total Gastrointestinal                  4,946        4,612           7            7           3,265             7
Cardiovascular:

Zestril                                   748          832         (10)         (10)            435           (12)
Seloken                                   652          554          18           17             445            27
Atacand                                   413          289          43           41             155            48
Plendil                                   355          332           7            6             151            13
Tenormin                                  275          300          (8)          (6)             42            (2)
Others                                    270          314         (14)         (15)             14           (70)
Total Cardiovascular                    2,713        2,621           4            4           1,242             6
Respiratory:
Pulmicort                                 580          570           2            1             246            23
Rhinocort                                 226          194          16           15             160            26
Symbicort                                 194           34         n/m          n/m               -             -
Accolate                                   95          115         (17)         (16)             66           (20)
Oxis                                       91           94          (3)          (5)              -             -
Others                                    106          116          (9)         (10)              -             -
Total Respiratory                       1,292        1,123          15           14             472            15
Oncology:
Zoladex                                   595          519          15           16             163             6
Casodex                                   465          393          18           18             138           (18)
Nolvadex                                  348          446         (22)         (21)            244           (27)
Arimidex                                  242          139          74           73             105           119
Iressa                                     26            -          n/m         n/m               -              -
Faslodex                                   19            -          n/m         n/m              19           n/m
Others                                     15           22         (32)         (32)              -              -
Total Oncology                          1,710        1,519          13           13             669            (5)
CNS:
Seroquel                                  804          526          53           53             651            49
Zomig                                     237          209          13           12             128             8
Others                                     23           16          44           44               5             -
Total CNS                               1,064          751          42           42             784            40
Pain, Infection and Other
Pharma:
Diprivan                                  331          329           1            2             163            10
Merrem                                    218          162          35           35              53            43
Local anaesthetics                        311          332          (6)          (5)             76           (17)
Other Pharma Products                     205          280         (27)         (27)             59           (31)
Total Pain, Infection and Other
  Pharma                                1,065        1,103          (3)          (3)            351            (3)
Salick Health Care                        170          144          18           18             170            18
Astra Tech                                108           90          20           19               8            60
Marlow Foods                               85           77          10            9               2             -
Total                                  13,153       12,040           9            9           6,963             8



n/m          not meaningful

8              THIRD QUARTER PRODUCT SALES ANALYSIS


                                                         World                                      US
                                        3rd            3rd                  Constant            3rd
                                      Quarter      Quarter       Actual     Currency        Quarter         Actual
                                         2002         2001       Growth       Growth           2002         Growth
                                           $m           $m            %            %             $m              %
Gastrointestinal:

Losec                                   1,223        1,421         (14)         (16)            798           (18)
Nexium                                    493          168         n/m          n/m             378           n/m
Others                                     15            9          67           67               4             -
Total Gastrointestinal                  1,731        1,598           8            6           1,180             6
Cardiovascular:

Zestril                                   189          188           1           (3)             84             2
Seloken                                   206          204           1           (2)            139            (1)
Atacand                                   132           93          42           33              38            31
Plendil                                   149          120          24           20              76            33
Tenormin                                   85           87          (2)          (5)              5           (38)
Others                                     89           94          (5)         (14)              3           (79)
Total Cardiovascular                      850          786           8            3             345             4
Respiratory:
Pulmicort                                 150          161          (7)         (12)             52           (10)
Rhinocort                                  80           64          25           22              60            30
Symbicort                                  72           20         n/m          n/m               -             -
Accolate                                   28           20          40           40              19            73
Oxis                                       30           29           3           (7)              -             -
Others                                     34           35          (3)         (12)              -             -
Total Respiratory                         394          329          20           13             131            14
Oncology:
Zoladex                                   208          175          19           14              58            12
Casodex                                   191          149          28           22              73             3
Nolvadex                                   86          160         (46)         (47)             51           (59)
Arimidex                                   96           47         104           98              42           163
Iressa                                     26            -         n/m          n/m               -             -
Faslodex                                   11            -         n/m          n/m              11           n/m
Others                                      4            7         (43)         (43)              -             -
Total Oncology                            622          538          16           12             235           (11)
CNS:
Seroquel                                  200          169          18           16             144             5
Zomig                                      69           55          25           18              30            67
Others                                      8           13         (38)         (38)              2             -
Total CNS                                 277          237          17           14             176            12
Pain, Infection and Other
Pharma:
Diprivan                                  105          114          (8)         (10)             50           (18)
Merrem                                     76           56          36           34              20            33
Local anaesthetics                        155          136          14           12              43             2
Other Pharma Products                      16           55         n/m          n/m               3           n/m
Total Pain, Infection and Other
  Pharma                                  352          361          (2)          (4)            116           (17)
Salick Health Care                         57           49          16           16              57            16
Astra Tech                                 37           28          32           18               3            50
Marlow Foods                               30           24          25           17               1             -
Total                                   4,350        3,950          10            6           2,244             4



n/m          not meaningful

Shareholder Information



ANNOUNCEMENTS AND MEETINGS




Annual Business Review                                   7 November 2002

Announcement of fourth quarter and full year 2002        30 January 2003
results

Announcement of first quarter 2003 results               30 April 2003

Annual General Meeting 2003                              30 April 2003

Announcement of second quarter and half year 2003        24 July 2003
results

Announcement of third quarter 2003 results               23 October 2003



DIVIDENDS




The record date for the first interim dividend paid on 7 October 2002 (in the
UK, Sweden and the US) was 23 August 2002.  Ordinary Shares traded ex-dividend
on the London and Stockholm Stock Exchange from 21 August 2002.  ADRs traded
ex-dividend on the New York Stock Exchange from the same date.



The record date for the second interim dividend for 2002 payable on 7 April 2003
(in the UK, Sweden and the US) will be 21 February 2003.  Ordinary Shares will
trade ex-dividend on the London and Stockholm Stock Exchange from 19 February
2003.  ADRs will trade ex-dividend on the New York Stock Exchange from the same
date.



Future dividends will normally be paid as follows:

First interim                                           Announced in July and paid in October
Second interim                                          Announced in January and paid in April



TRADEMARKS




The following brand names used in this interim report are trade marks of the
AstraZeneca group of companies:



Accolate  Arimidex  Astra Tech  Atacand  Atacand HCT   Casodex  Crestor
Diprivan  Exanta  Faslodex  Iressa  Losec   Merrem   Nexium  Nolvadex  Oxis
Plendil  Prilosec Pulmicort  Pulmicort Respules    Rhinocort  Rhinocort Aqua
Seloken  Seroquel  Symbicort  Tenormin  Toprol-XL   Zestril  Zoladex  Zomig
Zomig ZMT



ADDRESSES FOR CORRESPONDENCE




Registrar and                Depositary              Registered Office        Swedish Securities Register Centre
Transfer Office              for ADRs                                         VPC AB
The AstraZeneca Registrar    JPMorgan Chase Bank     15 Stanhope Gate         PO Box 7822
Lloyds TSB Registrars        PO Box 43013            London                   S-103 97 Stockholm
The Causeway                 Providence,             W1K 1LN                  Sweden
Worthing                     RI 02940-3013           UK
West Sussex                  US
BN99 6DA                                                                      
Tel: [phone]     Tel: [phone]  Tel: [phone] Tel: [phone]




CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

In order to utilise the 'Safe Harbor' provisions of the United States Private
Securities Litigation Reform Act of 1995, AstraZeneca is providing the following
cautionary statement.  This Interim Report contains forward-looking statements
with respect to the financial condition, results of operations and businesses of
AstraZeneca.  By their nature, forward-looking statements and forecasts involve
risk and uncertainty because they relate to events and depend on circumstances
that will occur in the future.  There are a number of factors that could cause
actual results and developments to differ materially from that expressed or
implied by these forward-looking statements.  These factors include, among other
things, exchange rate fluctuations, the risk that research and development will
not yield new products that achieve commercial success, the impact of
competition, price controls and price reductions, the risk of loss or expiration
of patents or trade marks, difficulties of obtaining and maintaining
governmental approvals for products, the risk of substantial product liability
claims and exposure to environmental liability.




                      This information is provided by RNS
            The company news service from the London Stock Exchange